Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan

Cephalalgia

Volumn 23, Issue 6, 2003, Pages 463-471

  Färkkilä, Markus ^a   Olesen, J ^b   Dahlof C ^c   Stovner, L J ^d   Ter Bruggen, J P ^e   Rasmussen, S ^f   Muirhead, N ^f   Sikes, C ^f  

^a Helsinki Headache Centre   (Finland)

^b KAS Glostrup   (Denmark)

^c Migränklinik Göterborg   (Sweden)

^d Nevrologisk Avdeling RIT   (Norway)

^e JEROEN BOSCH HOSPITAL   (Netherlands)

^f NONE

Author keywords

Efficacy; Eletriptan; Migraine; Sumatriptan; Triptan

Indexed keywords

ELETRIPTAN; SUMATRIPTAN;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERANCE; FEMALE; HUMAN; HYPESTHESIA; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THORAX DISEASE; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PYRROLIDINES; SUMATRIPTAN; TRYPTAMINES;

EID: 0038798478     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.2003.00554.x     Document Type: Article

References (19)

1. Tfelt-Hansen P. Sumatriptan for the treatment of migraine attacks - a review of controlled clinical trials. Cephalalgia 1993; 13:238-44.
2. 1B/1D receptor agonists in the acute treatment of migraine. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches. Philadelphia: Lippincott Williams & Wilkins, 2000:411-32.
3. Mathew NT, Kailasam J, Gentry P, Chernyshev O. Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial. Headache 2000; 40:464-5.
4. Stark S, Spierings EL, McNeal S, Putnam GP, Bolden-Watson CP, O'Quinn S. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 2000; 40:513-20.
5. Deleu D, Hanssens Y. Current and emerging second-generation triptans in acute migraine therapy: a comparative review. J Clin Pharmacol 2000; 40:687-700.
6. Millson DS, Tepper SJ, Rapoport AM. Migraine pharmacotherapy with oral triptans: a rational approach to clinical management. Expert Opin Pharmacother 2000; 1:391-404.
7. Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995; 47:5438.
8. 1B/1D agonist eletriptan following intravenous and oral administration. J Clin Pharmacol 2002; 42:528-39.
9. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJN, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31:291-4.
10. Goadsby PJ, Ferrari MD, Olesen J, Stovner LJ, Senard JM, Jackson NC et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. Neurol 2000; 54:156-63.
11. Breslau N, Rasmussen BK. The impact of migraine: epidemiology, risk factors, and co-morbidities. Neurology 2001; 56:S4-12.
12. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American migraine study II. Headache 2001; 41:646-57.
13. Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot®) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol 2002; 47:99-107.
14. Stark R, Dahlöf C, Haughie S, Hettiarachchi J. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a Phase III, multicentre, placebo-controlled study across three attacks. Cephalalgia 2001; 22:23-32.
15. 1 Receptors in migraine pathophysiology and treatment. Eur J Neurol 1995; 2:5-21.
16. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R. Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol 1999; 368:259-68.
17. Shah AK, Harris SC, Greenhalgh C, Morganroth J. The pharmacokinetics and safety of single escalating oral doses of eletriptan. J Clin Pharmacol 2002; 42:520-7
18. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60:1259-87.
19. Sandrini G, Färkkilä, M, Burgess G, Forster E, Haughie S. Eletriptan vs. sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Neurology 2002; 59(8):1210-17.